西藏药业：公司暂未开展慢性心衰适应症临床研究

互动易2025-07-08

有投资者向西藏药业提问，新活素慢性心衰Ⅲ期临床试验25年三季度可以顺利完成吗？据外界消息称，若试验顺利完成，新活素将获批用于慢性心衰治疗，可覆盖患者群体有望扩大三倍。贵公司每年研发费用是多少？公司回答表示，您好，感谢您对公司的关注。我公司新活素于2005年上市销售，主要适用于患有休息或轻微活动时呼吸困难的急性失代偿心力衰竭患者的静脉治疗。公司目前正在开展新活素上市后的循证医学探索性研究，暂未开展...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2549032512?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-07-08 16:52","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2549032512","market":"sh","top_or_hot":-1,"title":"西藏药业：公司暂未开展慢性心衰适应症临床研究","media":"互动易","content":"<div>\n<p>有投资者向西藏药业提问， 新活素慢性心衰Ⅲ期临床试验25年三季度可以顺利完成吗？据外界消息称，若试验顺利完成，新活素将获批用于慢性心衰治疗，可覆盖患者群体有望扩大三倍。贵公司每年研发费用是多少？公司回答表示，您好，感谢您对公司的关注。我公司新活素于2005年上市销售，主要适用于患有休息或轻微活动时呼吸困难的急性失代偿心力衰竭患者的静脉治疗。公司目前正在开展新活素上市后的循证医学探索性研究，暂未开展...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250708165635a43daa89&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>西藏药业：公司暂未开展慢性心衰适应症临床研究</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n西藏药业：公司暂未开展慢性心衰适应症临床研究\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-07-08 16:52 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250708165635a43daa89&s=b><strong>互动易</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>有投资者向西藏药业提问， 新活素慢性心衰Ⅲ期临床试验25年三季度可以顺利完成吗？据外界消息称，若试验顺利完成，新活素将获批用于慢性心衰治疗，可覆盖患者群体有望扩大三倍。贵公司每年研发费用是多少？公司回答表示，您好，感谢您对公司的关注。我公司新活素于2005年上市销售，主要适用于患有休息或轻微活动时呼吸困难的急性失代偿心力衰竭患者的静脉治疗。公司目前正在开展新活素上市后的循证医学探索性研究，暂未开展...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250708165635a43daa89&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"600211","symbol_name":"西藏药业","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250708165635a43daa89&s=b","article_id":"2549032512","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250708165635a43daa89&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2549032512","pubTimestamp":1751964756,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"有投资者向西藏药业提问， 新活素慢性心衰Ⅲ期临床试验25年三季度可以顺利完成吗？据外界消息称，若试验顺利完成，新活素将获批用于慢性心衰治疗，可覆盖患者群体有望扩大三倍。贵公司每年研发费用是多少？公司回答表示，您好，感谢您对公司的关注。我公司新活素于2005年上市销售，主要适用于患有休息或轻微活动时呼吸困难的急性失代偿心力衰竭患者的静脉治疗。公司目前正在开展新活素上市后的循证医学探索性研究，暂未开展慢性心衰适应症临床研究。公司每年研发费用具体情况请关注公司每年年报的相关章节。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"600211":"西藏药业","BK0239":"医药制造","BK0033":"西藏振兴"},"translate_title":"Tibet Pharmaceutical: The company has not yet carried out clinical research on indications for chronic heart failure","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600211":1},"content_text":"有投资者向西藏药业提问， 新活素慢性心衰Ⅲ期临床试验25年三季度可以顺利完成吗？据外界消息称，若试验顺利完成，新活素将获批用于慢性心衰治疗，可覆盖患者群体有望扩大三倍。贵公司每年研发费用是多少？公司回答表示，您好，感谢您对公司的关注。我公司新活素于2005年上市销售，主要适用于患有休息或轻微活动时呼吸困难的急性失代偿心力衰竭患者的静脉治疗。公司目前正在开展新活素上市后的循证医学探索性研究，暂未开展慢性心衰适应症临床研究。公司每年研发费用具体情况请关注公司每年年报的相关章节。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2549032512","isCrawlerRequest":true}